<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351636</url>
  </required_header>
  <id_info>
    <org_study_id>DSPC-ALM-1101</org_study_id>
    <nct_id>NCT01351636</nct_id>
  </id_info>
  <brief_title>Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients</brief_title>
  <acronym>AHOCEP</acronym>
  <official_title>Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients: An Open Labelled, Randomized, Multicentered, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Pharmaceutical (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality
      and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoints</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes for metabolism related index</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control in hypertensive haemodialysis patients</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Arotinolol Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antihypertensive medications plus arotinolol hydrochloride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non arotinolol group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Antihypertensive medications without arotinolol hydrochloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arotinolol Hydrochloride</intervention_name>
    <description>Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months</description>
    <arm_group_label>Arotinolol Hydrochloride</arm_group_label>
    <other_name>Almarl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non arotinolol group</intervention_name>
    <description>Antihypertensive medications without arotinolol for 18 months</description>
    <arm_group_label>Non arotinolol group</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18-75 years-old;

          -  Chronic kidney disease stage 5 with haemodialysis treatment for 2 months;

          -  Patients with blood pressureâ‰¥140/90 mmHg after receiving 2 or 3 antihypertensive
             medications for 2 weeks;

          -  Patients who receiving alfa or beta blockers will be washed out for 2 weeks;

          -  Written informed consent

        Exclusion Criteria:

          -  Unstable angina, myocardial infarction, symptomatic or continuous arrhythmia,
             cardiosurgery in the last 2 months;

          -  Patients who taking class I antiarrhythmic drugs;

          -  Resting heart rate less than 60;

          -  Patients with systolic pressure less than 90 mmHg;

          -  Patients with chronic obstructive pulmonary disease and asthma;

          -  Patients with cerebral infarction in the last 2 weeks;

          -  Severe disorders of liver function;

          -  Allergy to the arotinolol;

          -  Patients who planning to have kidney transplantation in the near future;

          -  Pregnancy and breast-feeding;

          -  Malignant tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nan Chen, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiaotong University Medical School Affiliated Ruijin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nan Chen</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2011</study_first_submitted>
  <study_first_submitted_qc>May 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2011</study_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic kidney disease</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Arotinolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

